Anergis (Switzerland) has gotten €4.5M from investors and is planning a phase IIb trial for ATIBAR, its leading candidate to treat Tree allergies.

anergis_allergy_allert_cop_phaseIIbAnergis is developing ultra-fast immunotherapies for allergies, which could be an interesting alternative to current treatments, known as ‘desensitization’ or conventional Allergy Immunotherapy (AIT).

This process of inducing tolerance to the allergen requires 3-5 years – time that could be saved with Anergis’ products.

ADVERTISEMENT

Following the completion of phase II trials, Anergis is advancing it leading programme, AllerT for birch allergies. A phase IIb trial is in the making, that will access efficacy and tolerability of two dosing regimens of AllerT In Adults with Birch Pollen AllergicRhinitis/ Rhinoconjunctivitis (ATIBAR).

anergis_allergy_ultra_fast_vaccine

Comparison of Anergis’ ultra-fast therapies with current standard therapies (Source: Anergis)

ATIBAR is expected to start in the Fall of 2016, with a total of 450 patients. Results are expected in the third quarter of 2017.

This trial is designed meet both European and US FDA efficacy criteria for allergy immunotherapy products. After this, one more confirmatory efficacy phase III trial will be required before registration, expects Vincent Charlon, CEO of Anergis.

Meanwhile, Anergis has closed a financing round extension with existing investors, which was worth around €4.5M (CHF 5M). Along with previous fundraisers, this should prepare the company for the first registration of AllerT.

anergis_cop_ultra_fast_allergy_vaccine

Anergis studies allergens to create a variety of COPs, to later be used as vaccines against allergies. (Source: Anergis)

Anergis’ products are based on its proprietary platform of Contiguous Overlapping Peptides (COPs), which consist of  long synthetic peptides, reproducing fragments of a selected allergen (foreign protein that triggers the allergic response).

AllerT is also in pre-clinical development for ragweed and dust mite allergies.

The allergy space has seen some recent successes. DBV Technologies from Paris (France) is developing a skin patch for food allergy, and it have been very successful lastly with now a market cap over €1Bn. Another Biotech is Circassia (UK), which has an extensive portfolio in allergies and asthma – and led the biggest Biotech IPO in 2014, raising €267M.

Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world affecting over 500 million people, so new therapies for allergies have the potential to tap into a big market.

Previous post

Biotech Environment in 2016: Reverse Engineering the Ecosystem #BES2016

Next post

How can we Optimise DNA Extraction from Human Blood for more Sensitive NGS Analysis?

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.